Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 37-42

  Casellas, J M ^a,b,f   Gilardoni, M ^a   Tome G ^a   Goldberg, M ^a   Ivanovic, S ^a   Orduna, M ^a   Dolmann, A ^c   Ascoli, M ^b   Ariza, H ^d   Montero, J M ^e  

^a Ctro de Estudios en Antimicrobianos   (Argentina)

^b Sanatorio San Lucas   (Argentina)

^c Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^d Hospital Mi Pueblo   (Argentina)

^e Hospital de San Fernando   (Argentina)

^f Centro Estudios en Antimicrobianos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; OFLOXACIN; ROXITHROMYCIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; CHRONIC BRONCHITIS; CONFERENCE PAPER; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MORAXELLA CATARRHALIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIA; BRONCHITIS; CHRONIC DISEASE; COMMUNITY-ACQUIRED INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; OFLOXACIN; PENICILLIN RESISTANCE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 0033051435     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Casellas, J. M., Blanco, M. G. & Pinto, M. E. (1994). The sleeping giant. Antimicrobial resistance. Infectious Disease Clinics of North America 8, 29-45.
2. Peixoto, S. (1989). Bacterial resistance in South America. International Journal of Gynecology and Obstetrics 2, Suppl., 3-5.
3. Casellas, J. M., Guevara, J. M., Guzmán, M., Pedreira, W. & Pinto, M. E. (1996). Boletin de la Asociación Panamericana de Infectologia, Montevideo, 2.
4. Finch, R. G. (1995). The role of new quinolones in the treatment of respiratory tract infections. Drugs 49, Suppl. 2, 144-51.
5. Cooper, B. & Lawlor, M. (1989). Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. American Journal of Medicine 87, 475.
6. Frieden, T. R. & Mangi, R. J. (1990). Inappropriate use of oral ciprofloxacin. Journal of the American Medical Association 26, 1438-40.
7. Gordon, J. J. & Kauffman, C. A. (1990). Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. American Journal of Medicine 89, 383-4.
8. Davis, R., Markham, A. & Balfour, J. A. (1996). Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51, 1019-74.
9. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
10. George, J. & Morrissey, I. (1997). The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 39, 719-23.
11. Bauernfeind, A. (1993). Comparative in-vitro activities of the new quinolone Bay y 3118 with ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. Journal of Antimicrobial Chemotherapy 31, 505-22.
12. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy, 40, 639-51.
13. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of CP 99219 compared with DU 6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and penicillin-resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-2.
14. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard. M7-A4. NCCLS, Wayne, PA.
15. Erwin, M. E. & Jones, R. N. (1993). Roxithromycin in-vitro susceptibility testing of Haemophilus influenzae by NCCLS methods. National Committee for Clinical Laboratory Standards. Journal of Antimicrobial Chemotherapy 32, 652-4.
16. Comité de l'Antibiogramme de la Société Française de Microbiologie (1996). Technical recommendations for in vitro susceptibility testing. Clinical Microbiology and Infection 2, Suppl. 1, S11-25.
17. Hammerschlag, M. R., Qumei, K. K. & Roblin, P. M. (1992). In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 36, 1573-4.
18. Baltch, A. L., Smith, R. P. & Ritz, W. (1995). Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrobial Agents and Chemotherapy 39, 1661-6.
19. Andrews, J. M., Honeybourne, D., Jevons, G., Brenwald, N. P., Cunningham, B. & Wise, R. (1997). Concentrations of levofloxacin (HR355) in the respiratory tract following a single oral dose in patients underoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 40, 573-7.
20. Cherubin, C. E., Eng, R. H. K., Smith, S. M. & Tan, E. N. (1992). A comparison of antimicrobial activity of ofloxacin, L-ofloxacin and other oral agents for respiratory tract pathogens. Diagnostic Microbiology and Infectious Disease 15, 141-44.
21. Eliopoulos, G. M., Wennersten, C. B. & Moellering, R. C. (1996). Comparative in vitro activity of levofloxacin and ofloxacin against Gram-positive bacteria. Diagnostic Microbiology and Infectious Disease 25, 35-41.
22. Flynn, C. M., Johnson, D. & Jones, R. N. (1996). In vitro efficacy of levofloxacin alone or in combination tested against multiresistant Pseudomonas aeruginosa strains. Journal of Chemotherapy 8, 411-5.
23. Drusano, G. L., Johnson, D. E., Rosen, M. & Standiford, H. C. (1993). Phamacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 37, 483-90.
24. Pascual, A., García, I. & Perea, E. J. (1990). Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrobial Agents and Chemotherapy 34, 277-80.